Replies to post #193706 on Biotech Values

[DewDiligence]

Praluent fallout…

REGN -3%
AMGN -3%
ESPR -23%
SNY -1%

[DewDiligence]

Re: Praluent/Repatha pricing

Praluent 75mg and 150mg doses will have same US price ($40/day list price), which removes a problem AMGN’s Repatha might have had if the two Praluent doses had been given different prices.

[DewDiligence]

FDA approves AMGN’s Repatha—label apparently similar to Praluent’s in excluding primary prevention in general population (but it differs from Praluent's label by including HoPH):

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm460082.htm

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.

Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, is approved for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease, such as heart attacks or strokes, who require additional lowering of LDL cholesterol [i.e. secondary prevention].

Emphasis added.

[DewDiligence]

AMGN +4%/AH on patent win blocking SNY/REGN’s Praluent from US market until 2029:

https://www.bloomberg.com/news/articles/2017-01-05/amgen-wins-ban-on-sanofi-s-sales-of-praluent-cholesterol-drug

U.S. District Judge Sue Robinson in Delaware ordered Sanofi and Regeneron to halt Praluent sales for 12 years because the drug infringes patents on Amgen’s Repatha medication.

…The sales ban takes effect in 30 days to give Sanofi time to ask an appeals court to lift the order or to “encourage the parties to reach an appropriate business resolution,” the judge said in a seven-page order. Otherwise, the patents expire in 2029….

REGN was halted before the news hit the wire and did not resume trading, as far as I know.